14 September 2017
Tusk Therapeutics appoints Matthew Hall as Chief Financial Officer
London and Stevenage, UK – 14 September 2017: Tusk Therapeutics, an immuno-oncology company, is pleased to announce the appointment of Matthew Hall as Chief Financial Officer.
Matthew is a seasoned finance professional with over 20 years’ corporate finance experience in a number of leading organisations and fast growing companies. Most recently Chief Financial Officer at Simbec-Orion Group, Matthew has extensive experience managing the day‐to‐day aspects of corporate activities, including P&L management, budgeting, financing, pre‐IPO funding, IPOs and M&A. Previously, Matthew was Chief Financial Officer at Sphere Medical Holding plc where he was appointed to lead the company’s successful IPO and prior to that was Chief Financial Officer of IS Pharma plc, where he was closely involved in the merger of IS Pharma plc and Sinclair Pharma plc to form Sinclair Pharma PLC. Matthew is a chartered accountant with a degree in economics.
“We are very pleased to have appointed someone of Matthew’s calibre to Tusk Therapeutics. Matthew is well respected in the industry and his experience and proven track record will be invaluable to the Company as we continue to mature and look to move our unique therapeutic antibodies into the clinic.”
Luc DochezChief Executive Officer of Tusk Therapeutics
“I am excited to be joining Tusk Therapeutics and am looking forward to contributing as the Company prepares to enter the next stage of its development.”
Matthew HallChief Financial Officer
- Ends –
For further information, please contact:
Luc Dochez, Chief Executive Officer
Consilium Strategic Communications
Julia Wilson, Lindsey Neville
+44 (0) 203 709 5708
About Tusk Therapeutics Ltd
Tusk Therapeutics is a privately held immuno-oncology company focused on discovering and developing therapeutic antibodies that harness the power of the immune system to transform the treatment of cancer. The Company has established a diversified pipeline of antibodies against both novel and validated targets that have the potential to address a broad range of solid and haematological cancer indications. The companies two lead programmes, CD38 an immunomodulator with a novel mechanism and CD25 a Treg depleting agent, are in preclinical development. The Company has strategic partnerships and licensing agreements with top research institutes including Cancer Research Technology, Cancer Research UK’s commercial arm and University College London. For further information about Tusk Therapeutics visit: www.tusktherapeutics.com